MX2023006294A - Proteinas de union a il-7 y su uso en tratamientos medicos. - Google Patents
Proteinas de union a il-7 y su uso en tratamientos medicos.Info
- Publication number
- MX2023006294A MX2023006294A MX2023006294A MX2023006294A MX2023006294A MX 2023006294 A MX2023006294 A MX 2023006294A MX 2023006294 A MX2023006294 A MX 2023006294A MX 2023006294 A MX2023006294 A MX 2023006294A MX 2023006294 A MX2023006294 A MX 2023006294A
- Authority
- MX
- Mexico
- Prior art keywords
- binding proteins
- medical therapy
- therapy
- medical
- theiruse
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063120564P | 2020-12-02 | 2020-12-02 | |
| PCT/EP2021/083465 WO2022117526A1 (en) | 2020-12-02 | 2021-11-30 | Il-7 binding proteins and their use in medical therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006294A true MX2023006294A (es) | 2023-06-13 |
Family
ID=78844686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006294A MX2023006294A (es) | 2020-12-02 | 2021-11-30 | Proteinas de union a il-7 y su uso en tratamientos medicos. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11802150B2 (https=) |
| EP (1) | EP4255928A1 (https=) |
| JP (1) | JP2023551935A (https=) |
| KR (1) | KR20230098288A (https=) |
| CN (1) | CN116547002A (https=) |
| AR (1) | AR124286A1 (https=) |
| AU (1) | AU2021391493C1 (https=) |
| CA (1) | CA3199648A1 (https=) |
| CL (1) | CL2023001556A1 (https=) |
| CO (1) | CO2023007851A2 (https=) |
| IL (1) | IL303134A (https=) |
| MX (1) | MX2023006294A (https=) |
| PH (1) | PH12023551170A1 (https=) |
| TW (1) | TWI821804B (https=) |
| WO (1) | WO2022117526A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023227641A1 (en) * | 2022-05-27 | 2023-11-30 | Glaxosmithkline Intellectual Property Development Limited | Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| AU2005269759A1 (en) | 2004-07-21 | 2006-02-09 | Glycofi, Inc. | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| US8961967B2 (en) * | 2009-11-30 | 2015-02-24 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
-
2021
- 2021-11-30 JP JP2023533733A patent/JP2023551935A/ja active Pending
- 2021-11-30 KR KR1020237018159A patent/KR20230098288A/ko active Pending
- 2021-11-30 MX MX2023006294A patent/MX2023006294A/es unknown
- 2021-11-30 WO PCT/EP2021/083465 patent/WO2022117526A1/en not_active Ceased
- 2021-11-30 AR ARP210103301A patent/AR124286A1/es unknown
- 2021-11-30 EP EP21823820.2A patent/EP4255928A1/en active Pending
- 2021-11-30 IL IL303134A patent/IL303134A/en unknown
- 2021-11-30 TW TW110144544A patent/TWI821804B/zh active
- 2021-11-30 CN CN202180081029.5A patent/CN116547002A/zh active Pending
- 2021-11-30 US US17/538,431 patent/US11802150B2/en active Active
- 2021-11-30 CA CA3199648A patent/CA3199648A1/en active Pending
- 2021-11-30 PH PH1/2023/551170A patent/PH12023551170A1/en unknown
- 2021-11-30 AU AU2021391493A patent/AU2021391493C1/en active Active
-
2023
- 2023-05-31 CL CL2023001556A patent/CL2023001556A1/es unknown
- 2023-06-15 CO CONC2023/0007851A patent/CO2023007851A2/es unknown
- 2023-09-05 US US18/460,944 patent/US12122828B2/en active Active
-
2024
- 2024-09-03 US US18/823,000 patent/US20240425581A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023551935A (ja) | 2023-12-13 |
| CN116547002A (zh) | 2023-08-04 |
| AU2021391493A1 (en) | 2023-06-08 |
| IL303134A (en) | 2023-07-01 |
| US11802150B2 (en) | 2023-10-31 |
| AU2021391493A9 (en) | 2024-05-23 |
| AU2021391493C1 (en) | 2026-04-16 |
| AR124286A1 (es) | 2023-03-15 |
| US20240025988A1 (en) | 2024-01-25 |
| CL2023001556A1 (es) | 2023-11-10 |
| KR20230098288A (ko) | 2023-07-03 |
| EP4255928A1 (en) | 2023-10-11 |
| TWI821804B (zh) | 2023-11-11 |
| PH12023551170A1 (en) | 2024-01-22 |
| WO2022117526A1 (en) | 2022-06-09 |
| US20240425581A1 (en) | 2024-12-26 |
| AU2021391493B2 (en) | 2025-10-30 |
| US12122828B2 (en) | 2024-10-22 |
| US20220169717A1 (en) | 2022-06-02 |
| TW202237183A (zh) | 2022-10-01 |
| CO2023007851A2 (es) | 2023-06-30 |
| CA3199648A1 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020252418A3 (en) | Novel interleukin-2 variants for the treatment of cancer | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| WO2018033254A3 (en) | Rna for cancer therapy | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2023009682A (es) | Inhibidores de tyk2 y sus usos. | |
| MX2026000948A (es) | Agentes heterobivalentes y homobivalentes dirigidos a la proteína alfa de activación de fibroblastos y/o al antígeno de membrana específico de próstata. | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| BR112023002458A2 (pt) | Métodos de tratamento da gota | |
| MX2023012271A (es) | Medicina terapeutica para enfermedades fibrosas. | |
| HUP0303927A2 (hu) | Anti-angiogén ágensek és TNF-alfa alkalmazása kombinációs kezelésre | |
| WO2022167816A3 (en) | Antibodies | |
| EP4548974A3 (en) | Somatostatin modulators and uses thereof | |
| MX2023009723A (es) | Inhibidores de tyk2 y sus usos. | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2023005971A (es) | Metodos y composicion para las modificaciones de kras. | |
| WO2022058618A3 (en) | Sars-cov2 antibodies | |
| MX2025008834A (es) | Proteinas de fusion anti-pd-1/il-2, composiciones farmaceuticas y aplicaciones terapeuticas | |
| WO2020180712A8 (en) | Anti-tnfr2 antibodies and uses thereof | |
| PH12023551170A1 (en) | Il-7 binding proteins and their use in medical therapy | |
| MX2023005346A (es) | Anticuerpo biespecifico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8. | |
| PH12021551174A1 (en) | Novel folr1 specific binding proteins for cancer diagnosis and treatment | |
| WO2024026308A3 (en) | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE | |
| WO2021004958A3 (en) | Compositions comprising bacterial strains | |
| MX2025008431A (es) | Proteinas de fusion fc de il-12 | |
| WO2007056301A3 (en) | Antibody therapy for treatment of diseases associated with gluten intolerance |